Omalizumab for the treatment of severe persistent allergic asthma.

Health technology assessment (Winchester, England)

Volumn 13 Suppl 2, Issue , 2009, Pages 31-39

  Jones, J ^a   Shepherd, J ^b   Hartwell, D ^b   Harris, P ^b   Cooper, K ^b   Takeda, A ^b   Davidson, P ^b  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; ANTIIDIOTYPIC ANTIBODY; MONOCLONAL ANTIBODY; OMALIZUMAB;

ASTHMA; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ANTI-ASTHMATIC AGENTS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; COST-BENEFIT ANALYSIS; HUMANS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

MLCS; MLOWN;

EID: 84886943179     PISSN: None     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta13suppl2/05     Document Type: Review

References (7)